For injured BC workers and first responders with an accepted WorkSafeBC claim for PTSD (post-traumatic stress disorder) or chronic pain, ketamine-assisted therapy is the most realistic psychedelic-adjacent treatment to pursue through workers' compensation in 2026. WorkSafeBC assesses all such requests case-by-case, based on clinical justification and documented conventional treatment failures. There is no formal drug formulary comparable to WSIB Ontario.

Key takeaways

WorkSafeBC reviews ketamine and esketamine requests case-by-case; there is no formal drug formulary listing for psychedelic-assisted therapy in BC.

BC's mental-health presumption (expanded June 2024) covers over 20 designated occupations, fast-tracking claim acceptance for PTSD, but does NOT auto-approve specific treatments.

CPSBC's ketamine guidance (updated August 2025) requires physician clinical justification; IV ketamine in non-hospital settings requires NHMSFAP facility authorization.

Psilocybin and MDMA are not formally listed on any WorkSafeBC formulary; access is only through Health Canada's Special Access Program (SAP), and approval rates declined sharply in 2025.

Workers who receive an adverse WorkSafeBC coverage decision have the right to request review from the Review Division and to appeal to the Workers' Compensation Appeal Tribunal (WCAT).

Multiple randomized controlled trials support ketamine for treatment-resistant PTSD: Feder et al. 2021 found 67% responder rates vs 20% for midazolam [N=30]; Beaglehole et al. 2025 found 81% at 1 mg/kg intramuscular [N=33].

What does WorkSafeBC cover for PTSD and chronic pain treatment?

WorkSafeBC reviews treatment requests for compensable PTSD and chronic pain claims individually. The board has no published drug formulary equivalent to WSIB Ontario's multi-formulary listing for ketamine and esketamine. Instead, WorkSafeBC's approach to emerging treatments follows its Evidence-Based Practice Group review process and adjudicates coverage on a claim-by-claim basis.

For PTSD specifically, WorkSafeBC's contracted PTSD Program provides trauma-focused psychotherapy (prolonged exposure, cognitive processing therapy, EMDR, and trauma-focused CBT) through contracted psychologists, Registered Clinical Counsellors (RCCs), and occupational therapists across BC [WorkSafeBC PTSD Program]. First-line pharmacotherapy recommendations are SSRIs and venlafaxine. Ketamine is not listed in the current WorkSafeBC PTSD Program framework.

For chronic non-cancer pain, WorkSafeBC's Evidence-Based Practice Group publishes periodic evidence reviews. The most recent review on IV and oral ketamine for chronic non-cancer pain was published in February 2026 (2025 update) [WorkSafeBC EBPG 2026]. The review found that existing evidence is primarily short-term, lacks a clear pattern in patient populations or treatment protocols, and that positive outcomes are mainly subjective in nature. WorkSafeBC does not derive a formal coverage recommendation from these reviews; they inform case-by-case adjudication.

Coverage for any treatment under WorkSafeBC depends on: an accepted compensable claim, a treating physician's clinical justification, documentation of prior conventional treatment failures, and WorkSafeBC case manager review. Workers retain the right to request review from WorkSafeBC's Review Division and to appeal adverse decisions to the Workers' Compensation Appeal Tribunal (WCAT).

For a cross-Canada comparison of workers' compensation coverage, see the parent guide: workers' compensation and psychedelic-assisted therapy in Canada.

WorkSafeBC's evidence reviews on ketamine — what the 2025 update says

WorkSafeBC's Evidence-Based Practice Group has published multiple clinical reviews on ketamine since 2022. These reviews signal institutional attention to the evidence base but do not constitute coverage approvals.

IV and Oral Ketamine for Chronic Non-Cancer Pain (2025 Update, published February 2026): The review examined studies published from 2022 to 2025 on IV ketamine's effectiveness for chronic non-cancer pain (CNCP), including questions about whether evidence supports application outside clinical trials, and on oral ketamine's potential. The group's conclusions were cautious: current studies provide mostly short-term evidence, with no clear pattern in pain type, patient demographics, or treatment protocols that would guide application of IV ketamine for CNCP in a workers' compensation context. Positive outcomes in the reviewed studies were primarily subjective, without corresponding improvement on functional outcomes [WorkSafeBC EBPG 2026].

Esketamine as Treatment for Depression and PTSD (April 2023): WorkSafeBC also published a separate evidence review on esketamine (the S-enantiomer of ketamine, approved by Health Canada as Spravato for treatment-resistant depression) specifically examining its role in depression and PTSD in compensable populations [WorkSafeBC Esketamine 2023]. The review's existence confirms WorkSafeBC monitors this field, but coverage remains case-by-case.

What this means in practice: A treating physician supporting a WorkSafeBC client's ketamine request cannot cite these reviews as endorsements. Instead, the physician's clinical justification letter must document the specific patient's compensable diagnosis, the conventional treatments already attempted and failed, and the clinical rationale for ketamine as the next step. WorkSafeBC will weigh this against the current evidence landscape.

Watch out: WorkSafeBC's reviews do not function like WSIB Ontario's formulary listings. There is no "tick the box" process. Clinical justification from the prescribing physician is the centrepiece of every coverage request.

BC's mental-health presumption — who is covered and what it means

British Columbia's mental-health presumption within the Workers Compensation Act significantly changed how WorkSafeBC processes PTSD and other mental disorder claims for designated occupations. Understanding what the presumption does (and does not) do is critical for anyone considering pursuing ketamine-assisted therapy through WorkSafeBC.

What the presumption does: Under BC's mental-health presumption, if a worker in a designated occupation experiences one or more traumatic events at work and develops a mental disorder, that disorder is presumed to have been caused by their work [BCMJ Presumptive Legislation]. WorkSafeBC bears the burden of proof if it wishes to deny on causation grounds. This substantially expedites claim acceptance and provides faster access to WorkSafeBC treatment funding for mental-health conditions including PTSD.

What the presumption does NOT do: The presumption applies to the underlying mental disorder diagnosis. It does not auto-approve any specific treatment, including ketamine-assisted therapy, psilocybin, or MDMA. Specific treatment coverage requires a separate clinical justification process.

Designated occupations as of June 2024 [BC Government News Release June 2024]:

The province expanded the mental-health presumption effective June 10, 2024, adding 11 new occupations. The full list now includes:

Firefighters (paid and volunteer, fire suppression duties)
Police officers
Emergency medical assistants and paramedics
Sheriffs
Corrections officers and wardens
Emergency dispatchers (fire, police, ambulance, 911)
Nurses (RNs, RPNs, LPNs, NPs)
Health care assistants and care aides
Forest firefighters and fire investigators
Firefighters working for Indigenous organizations
Community-integration specialists
Coroners
Harm-reduction workers
Parole officers and probation officers
Respiratory therapists
Shelter workers
Social workers
Transition house workers
Victim service workers
Withdrawal-management workers

The 2024 expansion meaningfully broadened coverage beyond traditional first-responder categories to include frontline social services, health, and community safety workers who face frequent traumatic exposure.

PTSD and ketamine — what the clinical evidence shows

Multiple randomized controlled trials support the use of ketamine for treatment-resistant PTSD, providing a body of evidence that treating physicians can draw on when justifying WorkSafeBC coverage requests.

Feder et al. (2021) published the first randomized controlled trial of repeated ketamine infusions for chronic PTSD in the American Journal of Psychiatry [Feder 2021]. In this double-blind, placebo-controlled trial (N=30), participants received six infusions of ketamine (0.5 mg/kg) or midazolam over two consecutive weeks. At week two, 67% of ketamine participants were treatment responders (at least 30% reduction in CAPS-5 scores) compared with 20% in the midazolam group (d=1.13; 95% CI 0.36–1.91). The authors concluded: "This randomized controlled trial provides the first evidence of efficacy of repeated ketamine infusions in reducing symptom severity in individuals with chronic PTSD."

Beaglehole et al. (2025) published a double-blind, active-controlled randomized crossover study in BJPsych Open examining intramuscular (IM) ketamine for treatment-resistant PTSD in a community sample (N=33) [Beaglehole 2025]. At 24 hours post-administration, responder rates were: 18% for the fentanyl control, 64% for ketamine 0.5 mg/kg, and 81% for ketamine 1.0 mg/kg. The authors concluded they provided "preliminary support for the efficacy and tolerability of i.m. ketamine in a community sample of individuals with PTSD." Effects persisted approximately one week post-administration.

Liu et al. (2024) published a meta-analysis and systematic review in Frontiers in Psychiatry specifically examining ketamine for chronic pain, depression, and PTSD in military populations (22 samples; 384 participants in ketamine groups) [Liu 2024]. Effect sizes were significant across all outcomes: PTSD (g=1.34), depression (g=2.06), and pain (g=1.75), all p less than 0.001. The authors noted: "The viability of ketamine as an alternative treatment may be particularly impactful for those who are treatment resistant."

For workers with comorbid PTSD and chronic pain, Dadabayev et al. (2020) conducted a randomized double-blind trial (N=41) comparing low-dose ketamine infusion to ketorolac in adults with comorbid PTSD and chronic pain [Dadabayev 2020]. Both treatments produced comparable improvement in PTSD and chronic pain symptoms persisting for seven days, supporting the dual-indication rationale for ketamine in workers with overlapping conditions.

Flynn et al. (2025) documented a six-week ketamine-assisted group psychotherapy (group-KAP — ketamine-assisted psychotherapy) program specifically for first responders and frontline healthcare workers experiencing work-related stress, trauma, anxiety, and depression [Flynn 2025]. Symptoms across all domains were significantly reduced from pre to post, suggesting community-based group-KAP may benefit first-responder populations relevant to WorkSafeBC claims.

Ketamine for chronic pain — the evidence relevant to BC workers

WorkSafeBC manages substantial chronic pain claims from industrial workers, construction workers, and others with compensable musculoskeletal, neuropathic, or CRPS (Complex Regional Pain Syndrome) injuries. The evidence base for ketamine in chronic non-cancer pain is relevant to these claims but remains cautious in WorkSafeBC's own assessment.

Current evidence supports ketamine's short-term analgesic effect in neuropathic and refractory chronic pain conditions, particularly CRPS (Complex Regional Pain Syndrome) and neuropathic pain that has failed conventional management [WorkSafeBC EBPG 2026; Dadabayev 2020]. In the Edmonton community ketamine program, Chrenek et al. (2023) documented that evidence can be applied to real-world clinical settings with complex patients and that sublingual or intranasal maintenance ketamine is feasible at approximately $100–150 per month, addressing the cost access barrier [Chrenek 2023].

However, WorkSafeBC's 2025 evidence review found that the positive outcomes reported in chronic pain studies are "mainly subjective in nature while lacking effectiveness on functional related outcomes" [WorkSafeBC EBPG 2026]. For WorkSafeBC purposes, functional outcomes, including return-to-work capacity, are central to coverage adjudication. This means a treating physician's clinical justification must address not only pain reduction but how ketamine therapy contributes to the worker's recovery and return-to-function goals.

Pro tip: Physicians submitting clinical justification to WorkSafeBC for ketamine in chronic pain should address both pain reduction evidence and functional/return-to-work outcomes. WorkSafeBC's primary mandate is occupational rehabilitation, not symptom management alone.

Psilocybin and MDMA — can a WorkSafeBC claim cover these?

Psilocybin and MDMA are not formally listed on any WorkSafeBC formulary or evidence-review endorsement for coverage at this time. Their legal access pathway in Canada is Health Canada's Special Access Program (SAP), which operates entirely separately from workers' compensation adjudication.

Psilocybin and MDMA are restricted drugs under Canada's Controlled Drugs and Substances Act. Patient access to psilocybin- or MDMA-assisted therapy is available only through Health Canada's Special Access Program (SAP). SAP approval is granted on a case-by-case basis and is not guaranteed. Approval rates declined sharply in 2025 [PsyCan 2025]. Psilocybin SAP is primarily approved for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA SAP is primarily approved for adults with PTSD [Health Canada SAP Notice].

MDMA-assisted therapy has the strongest PTSD-specific randomized controlled trial evidence base among psychedelics. Mitchell et al. (2021) found that 67% of MDMA-group participants no longer met PTSD diagnostic criteria at 18 weeks versus 32% in the placebo group in the MAPP1 Phase 3 trial (N=90) [Mitchell 2021]. The MAPP2 confirmatory trial (Mitchell 2023, N=104) replicated these findings in a demographically diverse population specifically including first responders and veterans [Mitchell 2023].

Notwithstanding this evidence, the practical reality for BC workers in 2026 is that WorkSafeBC case-by-case review of psilocybin or MDMA for PTSD is uncommon. Any such request would require SAP approval first, as a prerequisite, and then a separate WorkSafeBC coverage request. Workers pursuing this route should work closely with a treating physician familiar with both the SAP application process and WorkSafeBC adjudication.

CPSBC requirements for physicians prescribing ketamine in BC

Any physician prescribing ketamine for psychiatric or pain indications in British Columbia must follow CPSBC's interim guidance, updated August 11, 2025.

Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label and regulated by CPSBC (College of Physicians and Surgeons of British Columbia) [CPSBC IG-Ketamine, August 2025]. CPSBC's interim guidance applies to IM, oral, sublingual, and intranasal routes for mental health and chronic pain indications in community settings, and sets out four core requirements:

Informed consent: Physicians must obtain consent that meets the CPSBC Consent to Treatment practice standard. Off-label status must be disclosed.
Clinical justification: Treatment should "only be recommended when justified by the patient's condition and in the patient's best interest." This directly mirrors WorkSafeBC's own adjudication standard.
Transparent fees: Ketamine-assisted therapy is an uninsured service in BC; physicians must communicate fees clearly and fairly. If a WorkSafeBC claim is under consideration, the coverage status must be clarified in advance of treatment.
Advertising compliance: All patient communications must comply with CPSBC's Advertising and Communication with the Public practice standard.

For IV ketamine in a non-hospital setting, BC adds an additional layer: a physician must apply to the medical director of a Non-Hospital Medical/Surgical Facility (NHMSFAP) for authorization, and the authorizing physician's specialty is limited to critical care medicine, emergency medicine, or family practice anesthesia. This facility requirement adds logistical complexity compared with Alberta's CPSA framework, which does not require NHMSFAP authorization for IM, oral, or sublingual routes.

How to navigate a WorkSafeBC claim for ketamine therapy

For injured BC workers or first responders who have an accepted compensable claim and are exploring ketamine-assisted therapy, the process involves several sequential steps. WorkSafeBC does not have a streamlined prior-authorization pathway comparable to WSIB Ontario; each request is adjudicated as a novel or emerging treatment.

Step-by-step pathway:

Establish the compensable claim. PTSD and other mental disorders must be accepted as compensable before WorkSafeBC will consider treatment funding. For designated occupations (see list above), BC's mental-health presumption expedites this step. Non-presumption occupations require documented work-related causation.
Complete first-line treatment. WorkSafeBC expects trauma-focused psychotherapy and appropriate pharmacotherapy (SSRIs/venlafaxine) to be trialled first for PTSD; for chronic pain, appropriate analgesic and rehabilitative approaches must be documented as attempted.
Engage a qualified prescribing physician. In BC, this must be a CPSBC-registered physician following the IG-Ketamine interim guidance. For IV ketamine, the physician must operate within an NHMSFAP-authorized facility. For IM, oral, or sublingual routes, the community setting is more accessible.
Prepare clinical justification documentation. The treating physician provides WorkSafeBC with: the compensable diagnosis, all prior treatments attempted and their outcomes, the clinical rationale for ketamine, the proposed protocol (route, dose, number of sessions), and how the treatment supports the worker's return-to-function goals.
Submit to WorkSafeBC case manager for review. WorkSafeBC will review against the current evidence base, including its own Evidence-Based Practice Group publications.
If coverage is denied: Workers have the right to request review from WorkSafeBC's Review Division. If unsatisfied with the Review Division decision, workers can appeal to the Workers' Compensation Appeal Tribunal (WCAT), which is independent of WorkSafeBC.

Workers navigating a WorkSafeBC claim for ketamine therapy, or who have received an adverse decision, should consult a workers' compensation advocate or lawyer familiar with BC law. Workers' compensation legal aid services exist in BC to assist workers who cannot afford legal representation.

For a comparison of how other provincial workers' compensation boards handle these requests, see WCB Alberta and psychedelic-assisted therapy, which has a more established prior authorization framework including CRPS, refractory neuropathic pain, and presumptive PTSD for first responders.

What ATMA CENA offers for WorkSafeBC clients

ATMA CENA's role for injured BC workers and first responders exploring psychedelic-assisted therapy is primarily educational and navigational. The prescribing physician, the compensable claim, and the WorkSafeBC coverage decision are each outside ATMA CENA's control. What ATMA CENA can provide:

Care coordination for BC workers: For workers who have an existing therapeutic relationship with a psychologist, Registered Clinical Counsellor (RCC), or other mental health provider in BC, ATMA CENA's coordinated care network allows that existing provider to remain primary while ATMA CENA's clinical infrastructure provides the psychedelic-assisted therapy framework and dosing support.
Preparation and integration support: For workers who proceed to ketamine-assisted therapy under a BC-licensed prescribing physician, ATMA CENA can provide the psychotherapy preparation and integration components that enhance treatment outcomes, in coordination with the prescribing physician and WorkSafeBC's clinical team.

The medical prescription and CPSBC compliance for the dosing session itself is the responsibility of the prescribing physician. ATMA CENA supports the broader preparation, dosing, and integration process within the clinical framework.

Frequently asked questions

Does WorkSafeBC cover ketamine-assisted therapy?

WorkSafeBC reviews ketamine and esketamine coverage requests case-by-case for accepted compensable claims. There is no formal drug formulary listing for ketamine in BC comparable to WSIB Ontario's five-formulary framework. Coverage depends on the specific compensable diagnosis, documentation of prior conventional treatment failures, and clinical justification from the treating physician. Workers have the right to request review and appeal to WCAT if coverage is denied.

Who qualifies under BC's mental-health presumption?

As of June 10, 2024, over 20 designated occupations qualify, including firefighters, police, paramedics, sheriffs, corrections officers, emergency dispatchers, nurses, health care assistants, forest firefighters, coroners, social workers, parole officers, probation officers, respiratory therapists, shelter workers, harm-reduction workers, community-integration specialists, transition house workers, victim service workers, and withdrawal-management workers. The presumption fast-tracks diagnosis acceptance but does not auto-approve specific treatments.

What does BC's mental-health presumption actually provide?

The presumption means that if a worker in a designated occupation develops a mental disorder following workplace traumatic events, the disorder is presumed to be work-related. WorkSafeBC bears the burden of proof if it wants to deny on causation grounds. This significantly speeds claim acceptance. It does not, however, automatically authorize any specific treatment, including ketamine-assisted therapy.

Does WorkSafeBC cover psilocybin or MDMA for PTSD?

No. Neither psilocybin nor MDMA is formally listed on any WorkSafeBC formulary or evidence-review endorsement. Legal access requires Health Canada's Special Access Program (SAP). SAP approval rates declined sharply in 2025 and are not guaranteed. Any WorkSafeBC coverage request for SAP-approved psilocybin or MDMA would be a novel case.

What is CPSBC's position on ketamine prescribing?

CPSBC's interim guidance (updated August 2025) permits BC physicians to prescribe ketamine via IM, oral, sublingual, and intranasal routes for mental health and chronic pain indications in community settings, subject to four requirements: informed consent, clinical justification, transparent fee disclosure (it is uninsured in BC), and advertising compliance. IV ketamine in non-hospital settings requires additional NHMSFAP facility authorization and specific physician specialty credentials.

What is the appeals process if WorkSafeBC denies coverage?

Workers can request review from WorkSafeBC's Review Division. If unsatisfied, they can appeal to the Workers' Compensation Appeal Tribunal (WCAT), an independent tribunal. Legal aid and advocacy resources are available for BC workers who cannot afford representation.

Is ketamine approved by Health Canada for PTSD or chronic pain?

No. Ketamine is approved by Health Canada as an anaesthetic. Use for PTSD, depression, anxiety, and chronic pain is off-label, regulated provincially by CPSBC in British Columbia [CPSBC IG-Ketamine, August 2025].

Is esketamine (Spravato) different from IV ketamine for WorkSafeBC purposes?

Yes. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. IV ketamine is off-label. For WorkSafeBC purposes, both are assessed case-by-case without a formal formulary listing in BC, but the different regulatory status may factor into a clinical justification. WorkSafeBC published a specific evidence review on esketamine for depression and PTSD in April 2023 [WorkSafeBC Esketamine 2023].

How does the WorkSafeBC pathway differ from the WCB Alberta pathway?

WCB Alberta has a documented Pharmaceutical Ketamine and Esketamine procedure covering compensable CRPS, refractory neuropathic pain, and Bill 27 presumptive PTSD for first responders, making the Alberta prior authorization process more structured. WorkSafeBC has no equivalent formal procedure; all requests are adjudicated case-by-case. See WCB Alberta and psychedelic-assisted therapy for the Alberta framework.

Can I get ketamine therapy in BC and submit to WorkSafeBC for reimbursement?

The general approach is to seek WorkSafeBC coverage approval before beginning treatment rather than seeking retroactive reimbursement, which is harder to obtain. Work with your treating physician and WorkSafeBC case manager before committing to treatment costs.

Compliance disclaimer

Ketamine is approved by Health Canada as an anaesthetic. Its use for PTSD, depression, anxiety, and chronic pain is off-label and regulated by CPSBC (College of Physicians and Surgeons of British Columbia) [CPSBC IG-Ketamine, August 2025]. WorkSafeBC coverage for any treatment including ketamine is assessed case-by-case, is not automatic, and depends on the specific compensable claim, prior treatment history, and clinical justification provided by the prescribing physician. Workers have the right to request review and to appeal decisions to the Workers' Compensation Appeal Tribunal (WCAT).

This article is for informational purposes only and does not constitute medical advice, legal advice, or a guarantee of coverage. Consult your treating physician for individualized medical guidance and a workers' compensation lawyer or advocate for claim-specific legal advice.

Sources

WorkSafeBC Evidence-Based Practice Group (2026). Issues on IV Ketamine and Oral Ketamine for Chronic Non-Cancer Pain: 2025 Update. Published February 2026. https://www.worksafebc.com/en/resources/health-care-providers/guides/issues-on-iv-ketamine-and-oral-ketamine-for-chronic-non-cancer-pain-2025-update
WorkSafeBC Evidence-Based Practice Group (2023). Esketamine as Treatment for Depression and PTSD. April 2023. https://www.worksafebc.com/en/resources/health-care-providers/guides/esketamine-treatment-depression-ptsd
WorkSafeBC (2025). Post-Traumatic Stress Disorder (PTSD) Program. https://www.worksafebc.com/en/health-care-providers/rehabilitation/post-traumatic-stress-disorder-program
BC Government (2024). More workers will receive easier access to mental-health supports. News release, June 10, 2024. https://news.gov.bc.ca/releases/2024LBR0010-000892
BC Medical Journal (BCMJ). Presumptive legislation for work-related mental health injuries. https://bcmj.org/worksafebc/presumptive-legislation-work-related-mental-health-injuries
CPSBC — College of Physicians and Surgeons of British Columbia (2025). Interim Guidance: Ketamine Administration via Intramuscular, Oral, Sublingual, Intranasal Routes as Treatment for Mental Health Conditions and Chronic Pain in the Community Setting. Updated August 11, 2025. https://www.cpsbc.ca/files/pdf/IG-Ketamine-Administration-via-Intramuscular-Oral-Sublingual-Intranasal-Routes.pdf
CPSBC College Connector (2023). New and revised interim guidance on emerging treatments. https://www.cpsbc.ca/news/publications/college-connector/2023-V11-05/03
Feder, A., Costi, S., Rutter, S.B., et al. (2021). A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder. American Journal of Psychiatry, 178(2), 193–202. https://pubmed.ncbi.nlm.nih.gov/33397139/
Beaglehole, B., Glue, P., Neehoff, S., et al. (2025). Ketamine for treatment-resistant post-traumatic stress disorder: double-blind active-controlled randomised crossover study. BJPsych Open. https://pmc.ncbi.nlm.nih.gov/articles/PMC12529321/
Liu, J.J.W., Ein, N., Gervasio, J., et al. (2024). Ketamine in the effective management of chronic pain, depression, and posttraumatic stress disorder for Veterans: A meta-analysis and systematic review. Frontiers in Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1338581/full
Dadabayev, A.R., Joshi, S.A., Reda, M.H., et al. (2020). Low Dose Ketamine Infusion for Comorbid Posttraumatic Stress Disorder and Chronic Pain: A Randomized Double-Blind Clinical Trial. Chronic Stress (Thousand Oaks). https://pmc.ncbi.nlm.nih.gov/articles/PMC7758557/
Chrenek, C., Duong, H., Khullar, A., et al. (2024). Use of ketamine for treatment resistant depression: updated review of literature and practical applications to a community ketamine program in Edmonton, Alberta, Canada. Frontiers in Psychiatry. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1283733/full
Flynn, L., Rondeau, M., Krsak, M., Shannon, S. (2025). Ketamine-Assisted Group Therapy for Work-Related Stress in First Responders and Frontline Health Care Workers. Psychedelic Medicine. https://journals.sagepub.com/doi/abs/10.1089/psymed.2024.0050
Mitchell, J.M., et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine, 27(6), 1025–1033. https://pubmed.ncbi.nlm.nih.gov/33972795/
Mitchell, J.M., et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine, 29(10), 2473–2480. https://pubmed.ncbi.nlm.nih.gov/37709999/
PsyCan (2025). PsyCan Discovers Sharp Decline in Health Canada Approvals for Doctors Seeking Legal Psychedelic Therapy for Patients. https://psychedelicscanada.org/media/2025/09/psycan-discovers-sharp-decline-in-health-canada-approvals-for-doctors-seeking-legal-psychedelic-therapy-for-patients
Health Canada (2022). Notice to stakeholders: Requests to the Special Access Program (SAP) involving psychedelic-assisted psychotherapy. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
BCACC (2024). Health Canada Guidelines on Psychedelic-Assisted Therapy. https://bcacc.ca/wp-content/uploads/2024/10/Health-Canada-Guidelines-on-Psychedelic-Assisted-Therapy-2024.pdf
Workers' Compensation Appeal Tribunal (WCAT). Appeal a decision. https://www.wcat.bc.ca/home/appeal-a-decision/

Workers' Compensation and Psychedelic-Assisted Therapy in Canada — cross-provincial overview
WCB Alberta and Psychedelic-Assisted Therapy — comparison: Alberta has a formal ketamine procedure
Psychedelic-Assisted Therapy in Canada — what psychedelic-assisted therapy is and how it works
Psychedelics and PTSD — evidence base for psychedelics in PTSD treatment
What Is Ketamine-Assisted Therapy? — ketamine-assisted therapy explained

Last updated: 2026-05-06. Article is reviewed every 3 months (time-sensitive regulatory content).

WorkSafeBC and Psychedelic Therapy: What BC Workers Need to Know (2026)

Coverage rules differ by payer